ABP logo

AB Science BATS-CHIXE:ABP Stock Report

Last Price

€3.31

Market Cap

€141.0m

7D

0%

1Y

-60.3%

Updated

29 Nov, 2023

Data

Company Financials

ABP Stock Overview

A clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. More details

ABP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

AB Science S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for AB Science
Historical stock prices
Current Share Price€3.31
52 Week High€7.05
52 Week Low€3.31
Beta0.99
1 Month Change0%
3 Month Changen/a
1 Year Change-60.35%
3 Year Change-68.10%
5 Year Change-14.42%
Change since IPO-83.93%

Recent News & Updates

Recent updates

Shareholder Returns

ABPGB PharmaceuticalsGB Market
7D0%-1.7%-2.6%
1Y-60.3%-3.5%2.4%

Return vs Industry: ABP underperformed the UK Pharmaceuticals industry which returned -7.1% over the past year.

Return vs Market: ABP underperformed the UK Market which returned -2.4% over the past year.

Price Volatility

Is ABP's price volatile compared to industry and market?
ABP volatility
ABP Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.1%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.6%
10% least volatile stocks in GB Market2.6%

Stable Share Price: ABP has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ABP's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200189Alain Moussywww.ab-science.com

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications.

AB Science S.A. Fundamentals Summary

How do AB Science's earnings and revenue compare to its market cap?
ABP fundamental statistics
Market cap€140.97m
Earnings (TTM)-€16.88m
Revenue (TTM)€777.00k

181.4x

P/S Ratio

-8.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABP income statement (TTM)
Revenue€777.00k
Cost of Revenue€92.00k
Gross Profit€685.00k
Other Expenses€17.57m
Earnings-€16.88m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.33
Gross Margin88.16%
Net Profit Margin-2,173.10%
Debt/Equity Ratio-97.2%

How did ABP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/11/29 11:32
End of Day Share Price 2023/09/01 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AB Science S.A. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark van der GeestABN AMRO Bank N.V.
Michael RyskinBofA Global Research
Swayampakula RamakanthH.C. Wainwright & Co.